SEARCH:   Advanced

Blood, 1 December 2004, Vol. 104, No. 12, pp. 3483-3489. Prepublished online as a Blood First Edition Paper on August 17, 2004; DOI 10.1182/blood-2004-04-1311. This Article Full Text (PDF) All Versions of this Article: 2004-04-1311v1 104/12/3483    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Straus, D. J Articles by Yahalom, J. Search for Related Content PubMed PubMed Citation Articles by Straus, D. J Articles by Yahalom, J. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 9, 2004 Accepted June 20, 2004 Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) followed by radiation therapy (RT) vs. ABVD alone for stages I, II and IIIA non bulky Hodgkin's disease David J Straus*, Carol S Portlock, Jing Qin, Jane Myers, Andrew D Zelenetz, Craig Moskowitz, Ariela Noy, Andre Goy, and Joachim Yahalom Memorial Sloan-Kettering Cancer Center, New York, NY, USA * Corresponding author; email: strausd{at}mskcc.org. To determine whether combined modality therapy (CMT) is superior to chemotherapy alone (CT) , 152 untreated Hodgkin's disease patients with CS IA, IB, IIA, IIB, and IIIA without bulk disease were prospectively randomized to 6 cycles of ABVD alone or 6 cycles of ABVD followed by RT (3600 cGy: involved field for 11 patients, modified extended field for the rest). Sixty-five of 76 patients randomized to receive RT actually received it and 11 did not (4 progressed, 1 bleomycin toxicity, 6 refused ). For ABVD+RT, the complete remission (CR) percentage was 94% and no major response 6%. For ABVD alone, 94% achieved a CR, 1.5% a partial response (PR) and no major response 4.5%. At 60 months CR duration, freedom from progression (FFP), and overall survival (OS) for ABVD+ RT vs. ABVD alone are 91% vs. 87% (P=0.61), 86% vs. 81% (P=0.61) and 97% vs. 90% (P=0.08), respectively (logrank). The 95% confidence intervals for CR duration, FFP and OS differences at 5 years were (-8%, 15%), (-8%, 18%) and (-4%, 12%), respectively. Although significant differences were not seen, it is possible that a benefit in outcome of < 20% for CMT might be seen in a larger trial. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Hodgkin disease: the sword of Damocles resheathed Dan L. Longo Blood 2004 104: 3418. [Full Text] [PDF] This article has been cited by other articles: S. D. Smith and J. W. Sweetenham Studying Survival in Hodgkin's Lymphoma: All for One, or One for All? Why Methodology Matters Oncologist, August 1, 2009; 14(8): 814 - 815. [Full Text] [PDF] E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica, April 1, 2009; 94(4): 550 - 565. [Abstract] [Full Text] [PDF] A. Re, S. Ferrari, P. Frata, C. Pizzocaro, C. Crippa, A. Tucci, F. Facchetti, L. Grazioli, S.M. Magrini, and G. Rossi Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study Ann. Onc., May 1, 2008; 19(5): 951 - 957. [Abstract] [Full Text] [PDF] V. Pavone, U. Ricardi, S. Luminari, P. Gobbi, M. Federico, L. Baldini, E. Iannitto, G. Ucci, L. Marcheselli, L. Orsucci, et al. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study Ann. Onc., April 1, 2008; 19(4): 763 - 768. [Abstract] [Full Text] [PDF] J. Radford Limited-Stage Disease: Optimal Use of Chemotherapy and Radiation Treatment Hematology, January 1, 2008; 2008(1): 321 - 325. [Abstract] [Full Text] [PDF] C. Ferme, H. Eghbali, J. H. Meerwaldt, C. Rieux, J. Bosq, F. Berger, T. Girinsky, P. Brice, M. B. van't Veer, J. A. Walewski, et al. Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease N. Engl. J. Med., November 8, 2007; 357(19): 1916 - 1927. [Abstract] [Full Text] [PDF] A. Engert, J. Franklin, H. T. Eich, C. Brillant, S. Sehlen, C. Cartoni, R. Herrmann, M. Pfreundschuh, M. Sieber, H. Tesch, et al. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial J. Clin. Oncol., August 10, 2007; 25(23): 3495 - 3502. [Abstract] [Full Text] [PDF] N. Bartlett, D Niedzwiecki, J. Johnson, J. Friedberg, K. Johnson, K van Besien, A. Zelenetz, B. Cheson, G. Canellos, and For the Cancer Leukemia Group B Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 Ann. Onc., June 1, 2007; 18(6): 1071 - 1079. [Abstract] [Full Text] [PDF] A. Ng and P. Mauch The impact of treatment on the risk of second malignancy after Hodgkin's disease Ann. Onc., December 1, 2006; 17(12): 1727 - 1729. [Full Text] [PDF] E. Brusamolino, A. Baio, E. Orlandi, L. Arcaini, F. Passamonti, V. Griva, W. Casagrande, C. Pascutto, P. Franchini, and M. Lazzarino Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up. Clin. Cancer Res., November 1, 2006; 12(21): 6487 - 6493. [Abstract] [Full Text] [PDF] Y. S. Jhanwar and D. J. Straus The Role of PET in Lymphoma J. Nucl. Med., August 1, 2006; 47(8): 1326 - 1334. [Abstract] [Full Text] [PDF] J. Yahalom Don't Throw Out the Baby With the Bathwater: On Optimizing Cure and Reducing Toxicity in Hodgkin's Lymphoma J. Clin. Oncol., February 1, 2006; 24(4): 544 - 548. [Full Text] [PDF] B. F. Koontz, J. P. Kirkpatrick, R. W. Clough, R. G. Prosnitz, J. P. Gockerman, J. O. Moore, and L. R. Prosnitz Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against Complications J. Clin. Oncol., February 1, 2006; 24(4): 605 - 611. [Abstract] [Full Text] [PDF] M. K. Gospodarowicz and R. M. Meyer The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 253 - 258. [Abstract] [Full Text] [PDF] P. Das, C. S. Ha, and J. D. Cox Radiotherapy and Hodgkin's Lymphoma J. Clin. Oncol., December 1, 2005; 23(34): 8914 - 8915. [Full Text] [PDF] R. M. Meyer, M. K. Gospodarowicz, J. M. Connors, R. G. Pearcey, and L. E. Shepherd In Reply: J. Clin. Oncol., December 1, 2005; 23(34): 8915 - 8916. [Full Text] [PDF] D. L. Longo Radiation Therapy in Hodgkin Disease: Why Risk a Pyrrhic Victory? J Natl Cancer Inst, October 5, 2005; 97(19): 1394 - 1395. [Full Text] [PDF] G. P. Canellos Chemotherapy Alone for Early Hodgkin's Lymphoma: An Emerging Option J. Clin. Oncol., July 20, 2005; 23(21): 4574 - 4576. [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020